Low dose aspirin and pregnancy: how important is aspirin resistance?

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 123, Issue 9, 2016, Pages 1481-1487

  Navaratnam, K ^a   Alfirevic, A ^a   Alfirevic, Z ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Activation; aspirin; platelet; pre eclampsia; pregnancy; resistance

Indexed keywords

ACETYLSALICYLIC ACID;

CEREBROVASCULAR DISEASE; DRUG INDICATION; DRUG MECHANISM; DRUG RESISTANCE; DRUG TREATMENT FAILURE; HIGH RISK POPULATION; HISTORY OF MEDICINE; HUMAN; LOW DRUG DOSE; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACOGENETICS; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; THROMBOCYTE ACTIVATION; TREATMENT REFUSAL;

EID: 84978946832     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.13914     Document Type: Review

References (44)

1. NICE. Unstable Angina and Nstemi: The Early Management of Unstable Angina and Non-st Segment Elevation Myocardial Infarction. London: NICE, 2010.
2. NICE. Secondary Prevention. Secondary Prevention in Primary and Secondary Care for Patients Following a Myocardial Infarction. London: NICE, 2007.
3. NICE. Stroke and Transient Ischaemic Attack in Over 16s: Diagnosis and Initial Management. London: NICE, 2008.
4. NICE. Clopidogrel and Modified-Release Dipyridamole for the Prevention of Occlusive Vascular Events. London: NICE, 2008.
5. RCOG. Recurrent Miscarriage, Investigation and Treatment of Couples (Green-Top Guideline no. 17). London: RCOG, 2011.
6. NICE. Hypertension in Pregnancy. London: NICE, 2010.
7. RCOG. Small-for-Gestational-Age Fetus, Investigation and Management (Green-Top Guideline no. 31). London: RCOG, 2013.
8. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Fast track-articles: antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369:1791–8.
9. Xu TT, Zhou F, Deng CY, Huang GQ, Li JK, Wang XD. Low-dose aspirin for preventing preeclampsia and its complications: a meta-analysis. J Clin Hypertens 2015;17:567–73.
10. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606–17.
11. FitzGerald R, Pirmohamed M. Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther 2011;130:213–25.
12. Ebers G. Ebers Papyrus http://web.archive.org/web/20130921055114/http://oilib.uchicago.edu/books/bryan_the_papyrus_ebers_1930.pdf. Accessed 2 February 2016.
13. Stone E. An account of the success of the bark of the willow in the cure of agues. Philos Trans 1763;53:195–200.
14. Gerhardt C. Untersuchungen über die Wasserfreien organischen Säuren. Justus Liebigs Ann Chem 1853;87:149.
15. Zundorf U. Aspirin 100 Years: The Future Has Just Begun. Leverkusen: Bayer AG, 1997.
16. WHO [http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf]. Accessed 3 March 2015.
17. Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 2013;127:377.
18. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624–32.
19. Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood 1994;83:885–98.
20. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141 (2 Suppl):e89S–119S.
21. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336:195–8.
22. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004;110:e489–93.
23. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 2002;13:37–40.
24. Snoep JD, Hovens MC, Eikenboom JJ, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007;167:1593–9.
25. Marshall PW, Williams AJ, Dixon RM, Growcott JW, Warburton S, Armstrong J, et al. A comparison of the effects of aspirin on bleeding time measured using the Simplate(TM) method and closure time measured using the PFA-100(TM), in healthy volunteers. Br J Clin Pharmacol 1997;44:151–5.
26. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650–5.
27. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230.
28. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007;115:2196–207.
29. Neergaard-Petersen S, Ajjan R, Hvas A-M, Hess K, Larsen SB, Kristensen SD, et al. Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure. PLoS One 2013;8:1–8.
30. Wojtowicz A, Undas A, Huras H, Musial J, Rytlewski K, Reron A, et al. Aspirin resistance may be associated with adverse pregnancy outcomes. Neuro Endocrinol Lett 2011;32:334–9.
31. Caron N, Rivard G, Michon N, Morin F, Pilon D, Montquin J, et al. Low-dose ASA response using the PFA-100 in women with high risk pregnancy. J Obstet Gynaecol Can 2009;31:1022–7.
32. Rey E, Rivard G-E. Is testing for aspirin response worthwhile in high-risk pregnancy? Eur J Obstet Gynecol 2011;157:38–42.
33. Sullivan MHF, Elder MG. Changes in platelet reactivity following aspirin treatment for pre-eclampsia. BJOG 1993;100:542.
34. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71.
35. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366.
36. Patrono C, Patrono C. The multifaceted clinical readouts of platelet inhibition by low-dose aspirin. J Am Coll Cardiol 2015;66:74.
37. Evangelista V, de Berardis G, Totani L, Avanzini F, Giorda CB, Brero L, et al. Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. J Thromb Haemost 2007;5:2197.
38. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005;46:1258.
39. Hermida RC, Ayala DE, Fernandez JR, Mojon A, Alonso I, Silva I, et al. Administration time-dependent effects of aspirin in women at differing risk for preeclampsia. Hypertension 1999;34:1016.
40. Ayala DE, Ucieda R, Hermida R. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013;30:260.
41. Beitelshees AL, Voora D, Lewis JP. Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmacogenomics Pers Med 2015;8:43–61.
42. Voora D, Cyr D, Lucas J, Chi J-T, Dungan J, McCaffrey TA, et al. Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol 2013;62:1267.
43. Hyde C, Thornton S. Does screening for pre-eclampsia make sense? BJOG 2013;120:1168–70.
44. Werner EF, Hauspurg AK, Rouse DJ. A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States. Obstet Gynecol 2015;126:1242–50.